- Home
- NCZ vs SNN Comparison
NCZ vs SNN Comparison
Compare NCZ & SNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NCZ | SNN |
|---|---|---|
| Founded | 2003 | 1856 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Finance Companies | Industrial Specialties |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 288.7M | 12.3B |
| IPO Year | N/A | 2002 |
Fundamental Metrics
Financial Performance| Metric | NCZ | SNN |
|---|---|---|
| Price | $14.88 | $28.41 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $36.25 |
| AVG Volume (30 Days) | 35.9K | ★ 1.7M |
| Earning Date | 01-01-0001 | 03-16-2026 |
| Dividend Yield | ★ 12.16% | 2.48% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $8.58 |
| Revenue Next Year | N/A | $5.60 |
| P/E Ratio | ★ N/A | $64.97 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $12.95 | $27.23 |
| 52 Week High | $16.17 | $37.64 |
Technical Indicators
Market Signals| Indicator | NCZ | SNN |
|---|---|---|
| Relative Strength Index (RSI) | 35.59 | 44.02 |
| Support Level | $14.78 | N/A |
| Resistance Level | $15.87 | $31.36 |
| Average True Range (ATR) | 0.22 | 0.52 |
| MACD | -0.04 | -0.06 |
| Stochastic Oscillator | 2.60 | 50.00 |
Price Performance
Historical ComparisonAbout NCZ Virtus Convertible & Income Fund II of Beneficial Interest
Virtus Convertible & Income Fund II is a diversified, closed-end management investment company. The investment objective of the company is to provide total return through a combination of current income, current gains and long-term capital appreciation. Its portfolio of investments includes different sector investments such as in healthcare services, media, oil, gas, and consumable fuels and others.
About SNN Smith & Nephew SNATS Inc.
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound care solutions. Roughly 40% of the UK-based firm's revenue comes from orthopedic products, and another 31% is sports medicine and ENT. The remaining 29% of revenue is from the advanced wound therapy segment. Over half of Smith & Nephew's total revenue comes from the US, just over 30% is from other developed markets, and emerging markets account for the remainder.